Voyager Therapeutics doubles authorized shares to 240M following stockholder approval

Filed June 10, 2026 · Period ending June 9, 2026 · ~1 min read

Key Changes

• high

  Stockholders approved doubling authorized common stock from 120 million to 240 million shares, effective immediately upon Delaware filing June 9, 2026. This provides flexibility for future capital raises, acquisitions, or equity compensation but creates potential dilution risk for existing shareholders.

  Item 5.03 verify on EDGAR →
• medium

  Certificate of Amendment filed with Delaware Secretary of State on June 9, 2026, making the increased share authorization immediately effective. The company can now issue up to 240 million common shares with identical rights to existing stock.

  Item 5.03 verify on EDGAR →
• low

  Three Class II directors elected to serve until 2029: James Geraghty, Dr. Steven Hyman, and Dr. Alfred Sandrock. All received majority support with Dr. Sandrock receiving highest approval (96% votes for).

  Item 5.07 verify on EDGAR →